Ironwood Pharmaceuticals Inc
NASDAQ:IRWD

Watchlist Manager
Ironwood Pharmaceuticals Inc Logo
Ironwood Pharmaceuticals Inc
NASDAQ:IRWD
Watchlist
Price: 4.08 USD -5.12%
Market Cap: 663.7m USD

Net Margin
Ironwood Pharmaceuticals Inc

8.4%
Current
-61%
Average
-6.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
8.4%
=
Net Income
28.5m
/
Revenue
339m

Net Margin Across Competitors

No Stocks Found

Ironwood Pharmaceuticals Inc
Glance View

Ironwood Pharmaceuticals, Inc. is a healthcare company, which focuses on the development and commercialization of Gastrointestinal (GI) product opportunities in areas of significant unmet need, leveraging demonstrated expertise and capabilities in GI diseases. The company is headquartered in Boston, Massachusetts and currently employs 219 full-time employees. The company went IPO on 2010-02-03. The company operates in the human therapeutics business segment. Its product candidate LINZESS (linaclotide) is available to adult men and women suffering from IBS-C or CIC in the United States, and Mexico and to adult men and women suffering from IBS-C. Its linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC in Canada, and to adult men and women suffering from IBS-C in certain European countries. The Company’s products pipeline includes IW-3300, which is a GC-C agonist, for the potential treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis, and CNP-104 is a tolerizing immune modifying nanoparticle.

IRWD Intrinsic Value
7.89 USD
Undervaluation 48%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
8.4%
=
Net Income
28.5m
/
Revenue
339m
What is the Net Margin of Ironwood Pharmaceuticals Inc?

Based on Ironwood Pharmaceuticals Inc's most recent financial statements, the company has Net Margin of 8.4%.

Back to Top